SCHEMBL2192772

SCHEMBL2192772

Clc1ccc(CN(I)I)cc1.Cn1ccn(-c2ccccc2)c1=[Pt]

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 1/20 0.34
SIGMAR1 Q99720 2/20 0.32
TMEM97 Q5BJF2 1/20 0.32
ALDH1A1 P00352 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
HRH4 Q9H3N8 1/20 0.31
HRH3 Q9Y5N1 1/20 0.31
LSS P48449 1/20 0.31
G6PC1 P35575 1/20 0.31
BIRC5 O15392 1/20 0.31
CNR1 P21554 2/20 0.30
CNR2 P34972 2/20 0.30
KDM4E B2RXH2 1/20 0.30
TSHR P16473 1/20 0.30
SLC6A2 P23975 1/20 0.30
SLC6A4 P31645 1/20 0.30
SLC6A3 Q01959 1/20 0.30
GFER P55789 1/20 0.30
ATM Q13315 1/20 0.30
NPC1 O15118 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2195488 0.91 TSHR (0.34) SIGMAR1ALDH1A1KDM4ETSHRNPC1
SCHEMBL2196788 0.88 CYP2C19 (0.36) CYP19A1SIGMAR1TMEM97ALDH1A1CNR1
SCHEMBL2194277 0.87 BCHE (0.39) ALDH1A1TSHRKMT2A
SCHEMBL2192093 0.87 CYP19A1 (0.34) CYP19A1SIGMAR1ALDH1A1NPC1RAB9A
SCHEMBL2196965 0.85 ALOX15B (0.39) SIGMAR1TMEM97SLC6A2SLC6A4KMT2A
SCHEMBL2195803 0.85 LSS (0.37) CYP19A1SIGMAR1ALDH1A1LSSCNR1
SCHEMBL2194356 0.82 LMNA (0.32) NPC1RAB9AKMT2ALMNA
SCHEMBL2195398 0.79 TSHR (0.41) SIGMAR1ALDH1A1CNR2TSHRSLC6A2
SCHEMBL2193567 0.79 CYP11B1 (0.36) CYP19A1SIGMAR1TMEM97ALDH1A1NPSR1
SCHEMBL2195641 0.78 RAB9A (0.40) ALDH1A1LSSTSHRNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8980875-B2 Platinum-N-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2015-03-17 US claimed
US-20130338128-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2013-12-19 US claimed
US-8481522-B2 Platinum-N-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof SANOFI (FR) 2013-07-09 US claimed
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-07-14 US claimed
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130338128-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SCO2, C3AR1, IDH1 CYP19A1 787/4885SIGMAR1 259/4885TMEM97 2294/4885
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SCO2, C3AR1, IDH1 CYP19A1 787/4885SIGMAR1 259/4885TMEM97 2294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.